The above data demonstrate that the increasing HDAC activity results in an enhanced tumorigenicity, a greater proliferation ability, and an increased resistance to paclitaxel in NSCLC cells, giving the rationale for an efficacious therapeutic strategy. This evidence concerns the gene HDAC9 and non-small cell lung carcinoma.